Can-Fite BioPharma Ltd. (CANF)

NYSEAMERICAN: CANF · Real-Time Price · USD

3.390

+0.030 (0.89%)

At close: May 12, 2026, 4:00 PM EDT

3.300

-0.090 (-2.65%)

Pre-market: May 13, 2026, 4:53 AM EDT

Can-Fite BioPharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Can-Fite BioPharma stock has a target of 5.00, which predicts a 47.49% increase from the current stock price of 3.39.

Price Target: $5.00 (+47.49%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$5.00	$5.00	$5.00
Change	+47.49%	+47.49%	+47.49%	+47.49%

Analyst Ratings

The average analyst rating for Can-Fite BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $2.5 → $5	Strong Buy	Maintains	$2.5 → $5	+47.49%	May 12, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Dec 24, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $220 → $80	Strong Buy	Maintains	$220 → $80	+2,259.88%	Dec 17, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $220	Strong Buy	Maintains	$220	+6,389.68%	Nov 18, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $50	Strong Buy	Initiates	$50	+1,374.93%	Nov 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

11.00B

from 405.00K

2,715,455.56%

from 405.00K

Revenue Next Year

22.11B

from 11.00B

101.06%

from 11.00B

EPS This Year

n/a

from -5.97

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	853.00K	810.00K	743.00K	674.00K	405.00K	11.00B	22.11B
Revenue Growth	11.80%	-5.04%	-8.27%	-9.29%	-39.91%	2,715,455.56%	101.06%
EPS	-82.48	-37.41	-17.92	-10.86	-5.97	-	-
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	11.3B	45.5B
Avg	11.0B	22.1B
Low	10.6B	9.0M

Revenue Growth

Revenue Growth	2026	2027
High	2,795,208.6%	313.9%
Avg	2,715,455.6%	101.1%
Low	2,608,788.9%	-99.9%

EPS Forecast

EPS	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.